Literature DB >> 28645654

Epigenome dysregulation in cholangiocarcinoma.

Colm J O'Rourke1, Patricia Munoz-Garrido1, Esmeralda L Aguayo1, Jesper B Andersen2.   

Abstract

Epigenomics is a fast-evolving field of research that has lately attracted considerable interest, mainly due to the reversibility of epigenetic marks. Clinically, among solid tumors, the field is still limited. In cholangiocarcinoma (CCA) it is well known that the epigenetic landscape is deregulated both during carcinogenesis and disease progression as a consequence of aberrant mechanisms leading to genome instability. In this article, we will briefly review the molecular alterations that have been described in the transformation of normal cholangiocytes into malignant derivatives, focusing on the role of non-coding RNA (ncRNA) interactions, DNA methylation, post-translational modifications (PTMs) of histones and chromatin remodeling complexes.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biliary tract; Cholangiocarcinoma; Dysregulation; Epigenetics; Epigenome

Mesh:

Substances:

Year:  2017        PMID: 28645654     DOI: 10.1016/j.bbadis.2017.06.014

Source DB:  PubMed          Journal:  Biochim Biophys Acta Mol Basis Dis        ISSN: 0925-4439            Impact factor:   5.187


  12 in total

Review 1.  Cholangiocarcinoma 2020: the next horizon in mechanisms and management.

Authors:  Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-06-30       Impact factor: 46.802

Review 2.  Cholangiocarcinoma - evolving concepts and therapeutic strategies.

Authors:  Sumera Rizvi; Shahid A Khan; Christopher L Hallemeier; Robin K Kelley; Gregory J Gores
Journal:  Nat Rev Clin Oncol       Date:  2017-10-10       Impact factor: 66.675

3.  The Histone Methyltransferase G9a Promotes Cholangiocarcinogenesis Through Regulation of the Hippo Pathway Kinase LATS2 and YAP Signaling Pathway.

Authors:  Wenbo Ma; Chang Han; Jinqiang Zhang; Kyoungsub Song; Weina Chen; Hyunjoo Kwon; Tong Wu
Journal:  Hepatology       Date:  2020-10-09       Impact factor: 17.425

Review 4.  Cholangiocarcinoma: the role of genetic and epigenetic factors; current and prospective treatment with checkpoint inhibitors and immunotherapy.

Authors:  Panagiotis Sarantis; Eleftheria Dikoglou Tzanetatou; Evangelia Ioakeimidou; Christos Vallilas; Theodoros Androutsakos; Christos Damaskos; Nikolaos Garmpis; Anna Garmpi; Athanasios G Papavassiliou; Michalis V Karamouzis
Journal:  Am J Transl Res       Date:  2021-12-15       Impact factor: 4.060

5.  Epigenetic Silencing of 15-Hydroxyprostaglandin Dehydrogenase by Histone Methyltransferase EHMT2/G9a in Cholangiocarcinoma.

Authors:  Jinqiang Zhang; Weina Chen; Wenbo Ma; Kyoungsub Song; Sean Lee; Chang Han; Tong Wu
Journal:  Mol Cancer Res       Date:  2022-03-01       Impact factor: 6.333

Review 6.  Current challenges to underpinning the genetic basis for cholangiocarcinoma.

Authors:  Antonio Cigliano; Xin Chen; Diego F Calvisi
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2021-04-23       Impact factor: 3.869

Review 7.  Epigenetic Regulation of p21cip1/waf1 in Human Cancer.

Authors:  Matthias Ocker; Samar Al Bitar; Ana Carolina Monteiro; Hala Gali-Muhtasib; Regine Schneider-Stock
Journal:  Cancers (Basel)       Date:  2019-09-11       Impact factor: 6.639

Review 8.  Molecular Pathogenesis of Cholangiocarcinoma.

Authors:  Peter L Labib; George Goodchild; Stephen P Pereira
Journal:  BMC Cancer       Date:  2019-02-28       Impact factor: 4.430

9.  Integrative Analysis Defines Distinct Prognostic Subgroups of Intrahepatic Cholangiocarcinoma.

Authors:  Benjamin Goeppert; Reka Toth; Stephan Singer; Thomas Albrecht; Daniel B Lipka; Pavlo Lutsik; David Brocks; Marion Baehr; Oliver Muecke; Yassen Assenov; Lei Gu; Volker Endris; Albrecht Stenzinger; Arianeb Mehrabi; Peter Schirmacher; Christoph Plass; Dieter Weichenhan; Stephanie Roessler
Journal:  Hepatology       Date:  2019-02-28       Impact factor: 17.298

Review 10.  Molecular heterogeneity in intrahepatic cholangiocarcinoma.

Authors:  Keun Soo Ahn; Koo Jeong Kang
Journal:  World J Hepatol       Date:  2020-12-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.